PortfoliosLab logoPortfoliosLab logo
ZVRA vs. ERO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ZVRA vs. ERO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zevra Therapeutics Inc. (ZVRA) and Ero Copper Corp (ERO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ZVRA achieves a 41.18% return, which is significantly higher than ERO's 3.89% return.


ZVRA

1D
-2.47%
1M
13.76%
YTD
41.18%
6M
51.86%
1Y
35.01%
3Y*
29.54%
5Y*
-2.85%
10Y*
-16.40%

ERO

1D
6.10%
1M
-5.13%
YTD
3.89%
6M
16.30%
1Y
87.56%
3Y*
14.46%
5Y*
4.57%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ZVRA vs. ERO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ZVRA
Zevra Therapeutics Inc.
41.18%7.43%27.33%42.70%-47.30%-22.23%84.70%-78.71%-56.05%5.19%
ERO
Ero Copper Corp
3.89%109.87%-14.63%14.84%-10.07%-5.73%-10.97%151.68%21.41%52.76%

Correlation

The correlation between ZVRA and ERO is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Oct 23, 2017

0.13

Fundamentals

Market Cap

ZVRA:

$761.92M

ERO:

$3.09B

EPS

ZVRA:

$2.16

ERO:

$2.80

PE Ratio

ZVRA:

5.85

ERO:

10.51

PS Ratio

ZVRA:

5.94

ERO:

3.32

PB Ratio

ZVRA:

3.70

ERO:

2.80

Total Revenue (TTM)

ZVRA:

$122.29M

ERO:

$925.20M

Gross Profit (TTM)

ZVRA:

$104.94M

ERO:

$394.67M

EBITDA (TTM)

ZVRA:

$149.15M

ERO:

$528.87M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ZVRA vs. ERO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZVRA
ZVRA Risk / Return Rank: 6060
Overall Rank
ZVRA Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
ZVRA Sortino Ratio Rank: 6262
Sortino Ratio Rank
ZVRA Omega Ratio Rank: 6161
Omega Ratio Rank
ZVRA Calmar Ratio Rank: 6060
Calmar Ratio Rank
ZVRA Martin Ratio Rank: 5757
Martin Ratio Rank

ERO
ERO Risk / Return Rank: 7878
Overall Rank
ERO Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
ERO Sortino Ratio Rank: 7777
Sortino Ratio Rank
ERO Omega Ratio Rank: 7676
Omega Ratio Rank
ERO Calmar Ratio Rank: 7979
Calmar Ratio Rank
ERO Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZVRA vs. ERO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Ero Copper Corp (ERO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ZVRAERODifference
Sharpe ratioReturn per unit of total volatility

-0.96

Sortino ratioReturn per unit of downside risk

-0.71

Omega ratioGain probability vs. loss probability

1.16

1.26

-0.10

Calmar ratioReturn relative to maximum drawdown

0.81

2.32

-1.51

Martin ratioReturn relative to average drawdown

1.41

4.95

-3.54

ZVRA vs. ERO - Sharpe Ratio Comparison

The current ZVRA Sharpe Ratio is 0.56, which is lower than the ERO Sharpe Ratio of 1.52. The chart below compares the historical Sharpe Ratios of ZVRA and ERO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ZVRA vs. ERO - Drawdown Comparison

The maximum ZVRA drawdown since its inception was -99.27%, which is greater than ERO's maximum drawdown of -67.17%. Use the drawdown chart below to compare losses from any high point for ZVRA and ERO.


Loading charts...

Drawdown Indicators


ZVRAERODifference

Max Drawdown

Largest peak-to-trough decline

-99.27%

-67.17%

-32.10%

Max Drawdown (1Y)

Largest decline over 1 year

-43.47%

-37.97%

-5.50%

Max Drawdown (3Y)

Largest decline over 3 years

-43.47%

-59.84%

+16.37%

Max Drawdown (5Y)

Largest decline over 5 years

-74.01%

-63.89%

-10.12%

Max Drawdown (10Y)

Largest decline over 10 years

-97.85%

Current Drawdown

Current decline from peak

-96.65%

-22.72%

-73.93%

Average Drawdown

Average peak-to-trough decline

-86.41%

-27.04%

-59.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.87%

17.75%

+7.12%

Volatility

ZVRA vs. ERO - Volatility Comparison

The current volatility for Zevra Therapeutics Inc. (ZVRA) is 24.56%, while Ero Copper Corp (ERO) has a volatility of 26.23%. This indicates that ZVRA experiences smaller price fluctuations and is considered to be less risky than ERO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ZVRAERODifference

Volatility (1M)

Calculated over the trailing 1-month period

24.56%

26.23%

-1.67%

Volatility (6M)

Calculated over the trailing 6-month period

40.23%

47.36%

-7.13%

Volatility (1Y)

Calculated over the trailing 1-year period

62.90%

58.06%

+4.84%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.49%

55.03%

+5.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.46%

59.38%

+22.08%

Dividends

ZVRA vs. ERO - Dividend Comparison

Neither ZVRA nor ERO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ZVRA vs. ERO - Financials Comparison

This section allows you to compare key financial metrics between Zevra Therapeutics Inc. and Ero Copper Corp. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
36.22M
259.52M
(ZVRA) Total Revenue
(ERO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ZVRA and ERO have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ERO has higher volatility (26.23%) compared to ZVRA (24.56%). In terms of maximum drawdown, ZVRA dropped -99.27% vs ERO's -67.17%.

ERO currently has the higher Sharpe Ratio (1.52 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ZVRA and ERO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer